Atricure, Inc. ((ATRC)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: The clinical study titled The CryoICE™ Cryoanalgesia Registry for Pain Management in Post-cardiothoracic Surgery Via Cryoablation of the Intercostal Nerves aims to evaluate the outcomes of cryoablation of intercostal nerves for managing post-operative pain. This multicenter patient registry is significant as it seeks to improve pain management strategies following cardiothoracic surgery.
Intervention/Treatment: The study tests the AtriCure Cryo Nerve Block (cryoNB) Device Family, a device designed to perform cryoanalgesia, which is intended to alleviate post-operative pain by targeting intercostal nerves.
Study Design: This is an observational cohort study that includes both retrospective and prospective data collection. The study does not involve random allocation or masking, focusing instead on observing outcomes in patients who receive the cryoanalgesia treatment.
Study Timeline: The study began on October 28, 2021, with an estimated completion date in 2025. The most recent update was submitted on March 18, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might influence clinical practice and market dynamics.
Market Implications: This study update could positively impact AtriCure, Inc.’s stock performance by demonstrating the effectiveness of their cryoNB device in pain management, potentially increasing demand. Investors should watch for results that could influence market positioning, especially in comparison to competitors in the pain management device sector.
The study is currently ongoing, with further details available on the ClinicalTrials portal.